ARTHEx nabs Series B for clinical trial of ASO in myotonic dystrophy as Vertex’s deals heat up the space
03 May 2023
ARTHEx Biotech has raised €42 million (about $46 million) in Series B funds to bankroll an early-stage study of a drug candidate in myotonic dystrophy type 1, or DM1.
The Valencia, Spain-based startup will enter the clinic in the second half of this year with an IV-delivered drug candidate for people with the rare neuromuscular disorder.
Muscle weakness is a common result of DM1 and impacts about 40,000 people in the US and 70,000 in Europe. Those are the two geographies where ARTHEx will investigate ATX-01 in Phase I/IIa, said chair and new CEO Frédéric Legros in an interview.
Preview
Source: EndPoints
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 167,400+ biopharma pros reading Endpoints daily — and it's free.
SIGN UP
LOG IN
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.